Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rapid Micro Biosystems (RPID) Equity Average (2020 - 2025)

Rapid Micro Biosystems' Equity Average history spans 6 years, with the latest figure at $49.4 million for Q3 2025.

  • For Q3 2025, Equity Average fell 44.75% year-over-year to $49.4 million; the TTM value through Sep 2025 reached $49.4 million, down 44.75%, while the annual FY2024 figure was $96.7 million, 31.48% down from the prior year.
  • Equity Average for Q3 2025 was $49.4 million at Rapid Micro Biosystems, down from $60.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $227.9 million in Q4 2021 and bottomed at -$157.8 million in Q2 2021.
  • The 5-year median for Equity Average is $112.0 million (2024), against an average of $98.0 million.
  • The largest annual shift saw Equity Average soared 432.6% in 2022 before it tumbled 44.75% in 2025.
  • A 5-year view of Equity Average shows it stood at $227.9 million in 2021, then fell by 24.69% to $171.6 million in 2022, then fell by 28.38% to $122.9 million in 2023, then tumbled by 35.01% to $79.9 million in 2024, then crashed by 38.1% to $49.4 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's Equity Average are $49.4 million (Q3 2025), $60.0 million (Q2 2025), and $70.4 million (Q1 2025).